These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8177726)

  • 61. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
    Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
    Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
    Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
    Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
    Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989.
    Atkinson K; Nivison-Smith I; Dodds A; Concannon A; Milliken S; Downs K
    Bone Marrow Transplant; 1998 Apr; 21(7):691-5. PubMed ID: 9578309
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease.
    de la Cámara R; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Jul; 20(2):181. PubMed ID: 9244426
    [No Abstract]   [Full Text] [Related]  

  • 69. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevention and treatment of cytomegalovirus infection after marrow transplantation.
    Meyers JD
    Bone Marrow Transplant; 1988 Mar; 3(2):95-104. PubMed ID: 2844342
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytomegalovirus infections after allogeneic bone marrow transplantation.
    Winston DJ; Ho WG; Champlin RE
    Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Strategies for the prevention of cytomegalovirus disease after marrow transplantation.
    Goodrich JM; Boeckh M; Bowden R
    Clin Infect Dis; 1994 Aug; 19(2):287-98. PubMed ID: 7986901
    [TBL] [Abstract][Full Text] [Related]  

  • 73. DHPG at CMV viremia after allogeneic bone marrow transplantation. Result over a four year period (1986-1990).
    Milpied N; Harousseau JL; Moreau P; Lacroix F; Ramee JF; Billaudel S
    Bone Marrow Transplant; 1991; 7 Suppl 2():46. PubMed ID: 1652332
    [No Abstract]   [Full Text] [Related]  

  • 74. Prevention of early interstitial pneumonitis (IP) after BMT by exclusion of CMV-IG-POS platelet donors, prophylaxis with CMV immune globuline, and by a modified TBI regimen.
    Hinterberger W; Alth G; Höcker P; Kallinger W; Kier P; Kolbabek H; Lechner K; Popov-Kraup T
    Bone Marrow Transplant; 1991; 7 Suppl 2():43. PubMed ID: 1652329
    [No Abstract]   [Full Text] [Related]  

  • 75. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CMV immunoglobulin for prevention of pneumonitis after BMT.
    Klingemann HG; Phillips GL
    Bone Marrow Transplant; 1988 May; 3(3):235-6. PubMed ID: 2844345
    [No Abstract]   [Full Text] [Related]  

  • 77. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.
    Mori T; Aisa Y; Shimizu T; Nakazato T; Yamazaki R; Ikeda Y; Okamoto S
    Int J Hematol; 2006 Apr; 83(3):266-70. PubMed ID: 16720561
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prophylaxis of cytomegalovirus infection.
    Bowden RA; Meyers JD
    Semin Hematol; 1990 Apr; 27(2 Suppl 1):17-21; discussion 28-9. PubMed ID: 2160127
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied N; Fernandez Rañada JM; Mandelli F; Kho P; Kennedy L; Bell AR
    Lancet; 1994 Mar; 343(8900):749-53. PubMed ID: 7907729
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Issues concerning the use of intravenous immunoglobulins for the immunoprophylaxis of cytomegalovirus infections in allogeneic bone marrow transplant recipients.
    Emanuel D
    Monogr Allergy; 1988; 23():216-24. PubMed ID: 2838745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.